Trupanion, Inc.

Day range

$28.81 – $30.00

Open

$29.80

Prev close

$29.91

Volume

288.37K

Market cap

$1.31B

Shares out

43.87M

P/E

56.53

P/S

0.86

P/B

3.20

P/FCF

15.97

ROE

5.7%

ROA

2.5%

Debt/Equity

0.26

Div yield

0.00%

As of Oct 22, 2026

• Shareholder returnsAug 5, 2026

  In June 2026, the Company's Board of Directors (the "Board") approved a share repurchase program (the "Program") pursuant to which the Company is authorized to repurchase up to an aggregate of $100.0 million of its outstanding shares of common stock, with no expiration date.

• Shareholder meetingsJun 15, 2026

  On June 10, 2026, Trupanion, Inc. held its 2026 Annual Meeting, at which the Company's stockholders (i) elected the nine directors identified in the table below to the Board to serve until the Company's annual meeting of stockholders in 2027 or until their successors are duly elected and qualified, (ii) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, and (iii) approved the advisory vote on compensation for the Company's named executive officers for fiscal year ended December 31, 2025.

• Board of directorsApr 27, 2026

  On April 22, 2026, Max Brodén, a member of the Board of Directors (the "Board") of Trupanion, Inc. notified Trupanion that he will not stand for re-election at the upcoming Annual Stockholders' Meeting to be held at 9 am Pacific Time on June 10, 2026. Mr. Brodén decision not to stand for re-election was for personal reasons and not a result of any disagreement with Trupanion or the Board.

• Debt activityNov 6, 2025

  On November 4, 2025, Trupanion, Inc. (the "Company") and certain of its subsidiaries entered into a credit agreement (the "Credit Agreement") with PNC Bank, National Association, as the administrative agent. The Credit Agreement provides committed funds for (a) a term loan facility of $100.0 million (the "Term Facility"), and (b) a revolving credit facility of $20.0 million (the "Revolving Facility," and together with the Term Facility, the "Credit Facilities"). The Credit Facilities mature on November 4, 2028.

• Board of directorsOct 30, 2025

  On October 29, 2025, the board of directors (the "Board") of Trupanion, Inc. (the "Company") appointed Bradley S. Powell as a director. Mr. Powell, 65, served as Chief Financial Officer of Expeditors International of Washington, Inc. a publicly-traded global logistics company from October 2008 to September 2025. Prior to joining Expeditors, Mr. Powell served as Chief Financial Officer of Eden Bioscience Corporation, a publicly-traded biotechnology company, from July 1998 to September 2008, during which time he led the company through a successful initial public offering in 2000. He holds a B.S. in Accounting from Central Washington University. Mr. Powell was chosen to serve on the Board based on his accounting and financial acumen and his public company experience.

Days to cover

8.1

Short interest

3.88M

Avg volume

477.97K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• TRUP Lags Industry, Trades at a Premium: What Should Investors Know?
  neutralZacks Investment Research· Oct 1, 2026
• Lacy Pushes Trupanion Past $4 Billion in Paid Claims, Helping More than 3.9 Million Pets Receive Care
  positiveGlobeNewswire Inc.· May 26, 2026
• Trupanion Launches 2026 Veterinary Appreciation Day® Awards with New Team Excellence Category
  positiveGlobeNewswire Inc.· Apr 16, 2026
• Trupanion's CFO Just Sold His Last Share. The Filing Explains Why
  neutralThe Motley Fool· Mar 24, 2026
• PRISM MarketView Launches PetCare Index
  positiveGlobeNewswire Inc.· Feb 12, 2026